Clinical Trial

Normal-weight Diabetes: Adipocyte-directed Therapy With Pioglitazone or Tirzepatide

Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
This study is to investigate how adipocyte (fat cell) function and fat distribution differ between individuals with normal-weight type 2 diabetes (NWD), those with overweight type 2 diabetes (OWD), and normal-weight controls without diabetes (NWC). The study will assess whether adipocyte-directed therapies, specifically pioglitazone and tirzepatide, can improve insulin resistance, adipocyte function, and fat distribution in individuals with NWD. By analyzing the biological mechanisms underlying adipocyte dysfunction, the study aims to provide insights into novel treatment strategies for improving metabolic health in normal-weight individuals with type 2 diabetes.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-10-22.
Status change: Not Yet Recruiting → Recruiting 2026-04-15
Trial Details
NCT Number NCT06657209
Lead Sponsor Stanford University
Conditions Diabetes Mellitus, Type 2, Diabetes, Type 2 Diabetes, Pre Diabetes
Enrollment 104 participants
Start Date 2025-01-13
Primary Completion 2027-12-15 (estimated)
Study Completion 2027-12-15 (estimated)
Updated on ClinicalTrials.gov 2026-04-20